
Vilon dosage
What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.
- Regulatory status
- Not approved — research use only
- Human amounts
- None established in humans
- Route studied
- —
- Frequency
- Not established
- Half-life
- Not established
- Evidence grade
- Grade C · Preclinical research
- Vial sizes on the market
- 20 mg
- Other forms seen
- —
What Vilon is
Vilon is a short synthetic dipeptide of the bioregulator class, studied in experimental research on immune function and cellular aging.
No receptor or defined molecular target for vilon was identified in the sources reviewed. Its investigators place it, like the other short peptides in this family, in an epigenetic framework in which the dipeptide is proposed to reach chromatin and influence gene expression 3,5. Cellular observations In the human monocytic THP-1 line, vilon was one of five Khavinson peptides reported to increase tyrosine… How it works →
Key evidence
- Khavinson et al., Bulletin of Experimental Biology and Medicine · 2000 · Female CBA miceVilon was reported to increase physical activity and endurance, lower body temperature, prolong lifespan and prevent spontaneous neoplasms, with no effect on oestrous ageing or free radical processes. 1
- Pliss et al., Voprosy Onkologii (in Russian) · 2005 · Mice (1,2-dimethylhydrazine-induced carcinogenesis)Tumours were reported in 14.3% of vilon-treated animals surviving to first tumour detection at 46 weeks compared with 60% of controls, with reported inhibition of preneoplastic kidney changes. 2
- Avolio et al., International Journal of Molecular Sciences · 2022 · Human THP-1 monocyte/macrophage cell line (in vitro)Vilon was among five peptides reported to increase tyrosine phosphorylation of mitogen-activated cytoplasmic kinases and to lower lipopolysaccharide-induced TNF and IL-6 expression and adhesion to activated endothelial cells. 4
What the human evidence shows
We searched PubMed and ClinicalTrials.gov and found no human studies that administered Vilon. The research described on its page is from cells or animals, and animal amounts do not translate to people.
How long did human studies run?
No human study durations are recorded for Vilon.
Cycle-length evidence for VilonWho was excluded from the studies
- The only identified human report concerns elderly patients with stage III colorectal cancer 11.
Side effects reported in studies
- No adverse effect on development reported in the mouse lifespan studyNot quantified · Female CBA mice given long-term subcutaneous vilon 1
Vilon draw calculator
Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

Computed from your inputs. Not a dose or a recommendation.
Compare water volumes for this vialShow
More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.
| Water | mg/mL | Draw |
|---|---|---|
| 0.5 mL | 40 | — |
| 1 mL | 20 | — |
| 1.5 mL | 13.33 | — |
| 2 mL | 10 | — |
| 2.5 mL | 8 | — |
| 3 mL | 6.667 | — |
| 5 mL | 4 | — |
Supplies and handling
- Lyophilized vialSealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
- Sterile diluentThe diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
- Graduated syringesSized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
- Alcohol prep padsFor wiping vial stoppers before each puncture.
- Nitrile glovesClean gloves for aseptic handling.
- Sharps containerPuncture-resistant container for used needles.
Storage
General research-context handling only: lyophilised short peptides are normally kept cold, dry and protected from light, and reconstituted material is far less stable than the dry powder. Amiravo gives no preparation, reconstitution or handling instructions; defer to the supplier's own documentation and to local institutional requirements for research materials.
- Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
- Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
- Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.
Handling mistakes and troubleshooting
- Added the wrong volume of diluent
- The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
- Shook the vial and it foamed
- Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
- The solution is cloudy or has particles
- Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
- The powder cake looks melted or shrunken before reconstitution
- This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
- Liquid sprayed back when the needle was removed
- Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.
Regulatory status
- Status
- Not approved by the FDA for any use; no approved application and no structured product label were identified 6,7.
- United States (FDA)
- No approved application for this substance was identified in Drugs@FDA, and no structured product label for it was identified in DailyMed 7,8. It does not appear in any of the three categories of FDA's 503A bulk drug substances list as updated May 14, 2026 (Category 1, substances under evaluation; Category 2, substances raising significant safety risks; Category 3, substances nominated without adequate support) 9.
- Sport (WADA)
- The substance is not named anywhere in the WADA 2026 Prohibited List 10. Absence of a name is not a clearance: several classes on the List are written as open categories using wording such as "including, but not limited to", and section S0 (Non-Approved Substances) is written to cover pharmacological substances that are not addressed elsewhere on the List and that have no current approval from a governmental health authority for human therapeutic use, a description that fits an unapproved research peptide 10. Whether any particular substance falls inside S0 or inside an open class is a determination for anti-doping authorities, not something that can be read off the absence of a name.
Status varies by country and changes over time. How we describe regulatory status.
Vilon compared with related compounds
| Compound | Status | Evidence | Human amounts | Half-life |
|---|---|---|---|---|
| Vilon | Not approved — research use only | C | None established | — |
| Vesugen | Not approved — research use only | C | None established | — |
| Cortagen | Not approved — research use only | C | None established | — |
| Pinealon | Not approved — research use only | C | None established | — |
| Thymalin | Not approved — research use only | B | None established | — |
| Testagen | Not approved — research use only | D | None established | — |
Frequently asked questions
What doses of Vilon have been studied in humans?
Is there an established Vilon cycle length?
How much bacteriostatic water should be added to a Vilon vial?
How many units is a given amount on an insulin syringe?
References
- Effect of vilon on biological age and lifespan in mice Bull Exp Biol Med. 2000
- The effect of vilon (Lys-Glu) on 1.2-dimethylhydrazine-induced neoplasia Vopr Onkol. 2005
- Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum Biochemistry (Mosc). 2017
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line Int J Mol Sci. 2022
- Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture Bull Exp Biol Med. 2011
- Effects of short peptides on lymphocyte chromatin in senile subjects Bull Exp Biol Med. 2004
- Drugs@FDA: FDA-Approved Drugs (search of approved applications) FDA Drugs@FDA / openFDA drug/drugsfda. 2026
- DailyMed label search (structured product labels) NLM DailyMed. 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act, updated May 14, 2026 FDA. 2026
- World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026
- [Application of peptide bioregulator in complex treatment of elderly cancer patients] Adv Gerontol. 2005
Last reviewed October 23, 2026 by the Amiravo editorial team. Editorial policy · Report an error